Ashland pharmaceuticals

Visit us at CPHI Milan 2024

show dates: October 8-10, 2024
location: Milan, Italy
booth: 6D20

Ashland’s team of solvers is excited to meet you at CPHI Milan 2024 to showcase our latest products and innovations.

Discover the new klucel ls™ low-substituted hpc, a multifunctional binder and disintegrant for solid dosage forms.

We will introduce the industry’s most complete portfolio of controlled release products for all release profiles in oral and parenteral formulations.

Let’s discuss strategies to mitigate nitrosamine formation and learn more about our low nitrites excipients, polyplasdone™ LN crospovidone and benecel™ hypromellose.

When you're ready to formulate, we're ready to work with you.

Visit with us to learn more about the ways we are always solving™

  Ashland polyplasdone

key products

  • vialose™ trehalose dihydrate is a premier performance sugar resistant to acid hydrolysis and enzymatic cleavage. It is used to protect and shield biologic APIs, recombinant proteins, and monoclonal antibodies (mAbs) from degradation and aggregation and to stabilize and protect valuable components during the lyophilization process.
     
  • viatel™ bioresorbable polymers control release over time. These polymers are the building blocks for developing long-acting injectable depots, an established technology to improve therapeutic efficacy and patient compliance. All viatel™ bioresorbable polymers can be custom produced.
     
  • klucel™ xtend hydroxypropyl cellulose (HPC) controlled release matrix former, designed to deliver unsurpassed process versatility and release profile efficiency. Ashland’s step change klucel™ xtend HPC, has been shown to match the release profile of hypromellose controlled-release formulations at half the polymer concentration.
     

  • klucel fusion™ HPC is the only binder designed for melt granulation. It delivers stellar, immediate release tablet binding performance at a significantly lower melt processing temperature.

  • benecel™ xrf hpmc are fine particle grades designed for optimal performance in large-scale, high speed tableting. This product provides better powder flowability, produces robust tablets under high-throughput continuous manufacturing conditions and for challenging multi-layer sustained release tablets, and with lower nitrosamine levels, improves formulation stability by minimizing the potential for interaction between API and excipients that results in NDMA.

  • polyplasdone™ LN superdisintegrant, a high-purity crospovidone with low and controlled nitrite specification to manage nitrosamines challenges effectively. Polyplasdone™ LN grades maintain the renowned performance and reliability of the Polyplasdone™ brand. Featuring significantly reduced nitrite levels at no more than 100 ppb.

We offer the broadest selection of ingredients to compose effective pharmaceutical excipients. Migrating towards high impact and high value, we are widening our portfolio of cellulose-based polymers (HPMC, HPC, CMC, HEC), growing our excipient portfolio for injectables/biologics, including the possibility for customization, and focusing on film coatings. Oral solid dosage and liquid dosage ingredients, controlled release functionality, coatings, disintegrants, binders, and now, injectables compose Ashland’s pharma portfolio, and it is the diamond at the center of Ashland.

lower left image lower left image

 

 

lower left image lower left image

contact us

Fill out the form below and we'll contact you to arrange a meeting.

By checking the subscribe box and submitting this form, I agree to my email address being stored and used to receive promotional emails from Ashland, and I acknowledge that I have read and understand the Ashland privacy policy.